Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Polaris Venture Capital is committed to building successful enterprises through value-added partnerships with promising technology companies. With the recent closing of Polaris Fund III, and the merger of the management team of Polaris with the Eucalyptus Ventures management team, Polaris Venture Capital is by far the largest and most experienced venture capital management group originating in Israel. Possessing vast experience in equity investments and high-technology management, Polaris Venture Capital is now managing over $700 million.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
6/2005 | ClearView Audio | Series A | 7M |
8/2008 | ClearView Audio | Venture Round | 4M |
5/2007 | ClearView Audio | Venture Round | 3M |
2/2001 | Phonetic Systems | Private Equity Round | 0 |
5/2008 | Selecta Biosciences | Seed Round | 2.5M |
12/2017 | Respicardia | Venture Round | 0 |
3/2013 | Avitide | Series A | 1.4M |
7/2009 | Avila Therapeutics | Series B | 30M |
8/2000 | SercoNet | Series B | 5M |
3/2015 | aTyr Pharma | Series E | 76M |
2/2006 | Imprivata | Series B | 12M |
6/2013 | Ocular Therapeutix | Series D | 23.8M |
3/2019 | NakedPoppy | Seed Round | 4.1M |
2/2021 | Seraxis | Series C | 40M |
11/1999 | Vigil Technologies, Inc. | Series B | 5.5M |
5/2017 | Cardlytics | Series G | 0 |
3/2006 | Allurent | Series A | - |
9/2018 | Lyra Therapeutics | Series B | 0 |
2/2021 | Seraxis | Series C | 0 |
3/2019 | NakedPoppy | Seed Round | 0 |
9/2018 | Lyra Therapeutics | Series B | 0 |
12/2017 | Respicardia | Venture Round | 0 |
5/2017 | Cardlytics | Series G | 0 |
3/2015 | aTyr Pharma | Series E | 0 |
6/2013 | Ocular Therapeutix | Series D | 0 |
3/2013 | Avitide | Series A | 0 |
7/2009 | Avila Therapeutics | Series B | 0 |
8/2008 | ClearView Audio | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|